About Us


BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: To find a complete list of Publications, please see listing here.


Found 5 results
Filters: Author is McCarthy, Philip  [Clear All Filters]
A. Dispenzieri, Krishnan, A., Arendt, B., Blackwell, B., Wallace, P. K., Dasari, S., Vogl, D. T., Efebera, Y., Fei, M., Geller, N., Giralt, S., Hahn, T., Howard, A., Kohlhagen, M., Landau, H., Hari, P., Pasquini, M. C., Qazilbash, M. H., McCarthy, P., Shah, N., Vesole, D. H., Stadtmauer, E., and Murray, D., Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)., Blood Cancer J, vol. 12, no. 2, p. 27, 2022.
Q. Bashir, Nishihori, T., Pasquini, M. C., Martens, M. J., Wu, J., Alsina, M., Anasetti, C., Brunstein, C., Dawson, P., Efebera, Y., Gasparetto, C., Geller, N., Giralt, S., Hall, A. C., Koreth, J., McCarthy, P., Scott, E., Stadtmauer, E. A., Vesole, D. H., and Hari, P., A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial., Transplant Cell Ther, 2022.
A. D'Souza, Brazauskas, R., Stadtmauer, E. A., Pasquini, M. C., Hari, P., Bashey, A., Callander, N., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Landau, H., Brunstein, C., McCarthy, P., Qazilbash, M. H., Giralt, S., Krishnan, A., and Flynn, K. E., Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma., Am J Hematol, 2022.